Cargando…

The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response

Given their intrinsic pleiotropism, microRNAs (miR) play complex biological roles, in both normal and pathological conditions. Often the same miR can act as oncogene or oncosuppressor, depending on the biological process dysregulated in each specific tissue. miR‐223 does not represent an exception t...

Descripción completa

Detalles Bibliográficos
Autores principales: Favero, Andrea, Segatto, Ilenia, Perin, Tiziana, Belletti, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518860/
https://www.ncbi.nlm.nih.gov/pubmed/33951281
http://dx.doi.org/10.1002/wrna.1659
_version_ 1784584325697634304
author Favero, Andrea
Segatto, Ilenia
Perin, Tiziana
Belletti, Barbara
author_facet Favero, Andrea
Segatto, Ilenia
Perin, Tiziana
Belletti, Barbara
author_sort Favero, Andrea
collection PubMed
description Given their intrinsic pleiotropism, microRNAs (miR) play complex biological roles, in both normal and pathological conditions. Often the same miR can act as oncogene or oncosuppressor, depending on the biological process dysregulated in each specific tissue. miR‐223 does not represent an exception to this rule and its functions greatly differ in different contexts. miR‐223 has been widely studied in the hematopoietic compartment, where it plays a central role in innate immune response, regulating myeloid differentiation and granulocytes function. Accordingly, dysregulated expression of miR‐223 has been associated to different inflammatory disorders and tumors arising from the immune compartment. Most carcinomas, breast cancer being the most studied, display loss of miR‐223. However, in gastro‐esophageal cancers miR‐223 is frequently overexpressed and correlates with worse prognosis. A link between miR‐223 and response to CDK4/6‐inhibitors has been recently proposed, suggesting a role as biomarker of therapeutic response. The notion that one of the most commonly mutated protein in cancer, mutant p53, binds the promoter of miR‐223 and suppresses its transcription, adds a further level of complexity to the full understanding of miR‐223 in cancer. In this review, we will summarize the current knowledge on the molecular networks that alter or are altered by miR‐223, in different cancer types. We will discuss if the times are ready for the exploitation of miR‐223 as predictive biomarker of treatment response or, even, as therapeutic target, in specific settings. Finally, we will suggest which could be the next steps to be taken for a realistic clinical application of miR‐223. This article is categorized under: RNA in Disease and Development > RNA in Disease;
format Online
Article
Text
id pubmed-8518860
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-85188602021-10-21 The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response Favero, Andrea Segatto, Ilenia Perin, Tiziana Belletti, Barbara Wiley Interdiscip Rev RNA Advanced Reviews Given their intrinsic pleiotropism, microRNAs (miR) play complex biological roles, in both normal and pathological conditions. Often the same miR can act as oncogene or oncosuppressor, depending on the biological process dysregulated in each specific tissue. miR‐223 does not represent an exception to this rule and its functions greatly differ in different contexts. miR‐223 has been widely studied in the hematopoietic compartment, where it plays a central role in innate immune response, regulating myeloid differentiation and granulocytes function. Accordingly, dysregulated expression of miR‐223 has been associated to different inflammatory disorders and tumors arising from the immune compartment. Most carcinomas, breast cancer being the most studied, display loss of miR‐223. However, in gastro‐esophageal cancers miR‐223 is frequently overexpressed and correlates with worse prognosis. A link between miR‐223 and response to CDK4/6‐inhibitors has been recently proposed, suggesting a role as biomarker of therapeutic response. The notion that one of the most commonly mutated protein in cancer, mutant p53, binds the promoter of miR‐223 and suppresses its transcription, adds a further level of complexity to the full understanding of miR‐223 in cancer. In this review, we will summarize the current knowledge on the molecular networks that alter or are altered by miR‐223, in different cancer types. We will discuss if the times are ready for the exploitation of miR‐223 as predictive biomarker of treatment response or, even, as therapeutic target, in specific settings. Finally, we will suggest which could be the next steps to be taken for a realistic clinical application of miR‐223. This article is categorized under: RNA in Disease and Development > RNA in Disease; John Wiley & Sons, Inc. 2021-05-05 2021 /pmc/articles/PMC8518860/ /pubmed/33951281 http://dx.doi.org/10.1002/wrna.1659 Text en © 2021 The Authors. WIREs RNA published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Advanced Reviews
Favero, Andrea
Segatto, Ilenia
Perin, Tiziana
Belletti, Barbara
The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
title The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
title_full The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
title_fullStr The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
title_full_unstemmed The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
title_short The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
title_sort many facets of mir‐223 in cancer: oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
topic Advanced Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518860/
https://www.ncbi.nlm.nih.gov/pubmed/33951281
http://dx.doi.org/10.1002/wrna.1659
work_keys_str_mv AT faveroandrea themanyfacetsofmir223incanceroncosuppressoroncogenicdrivertherapeutictargetandbiomarkerofresponse
AT segattoilenia themanyfacetsofmir223incanceroncosuppressoroncogenicdrivertherapeutictargetandbiomarkerofresponse
AT perintiziana themanyfacetsofmir223incanceroncosuppressoroncogenicdrivertherapeutictargetandbiomarkerofresponse
AT bellettibarbara themanyfacetsofmir223incanceroncosuppressoroncogenicdrivertherapeutictargetandbiomarkerofresponse
AT faveroandrea manyfacetsofmir223incanceroncosuppressoroncogenicdrivertherapeutictargetandbiomarkerofresponse
AT segattoilenia manyfacetsofmir223incanceroncosuppressoroncogenicdrivertherapeutictargetandbiomarkerofresponse
AT perintiziana manyfacetsofmir223incanceroncosuppressoroncogenicdrivertherapeutictargetandbiomarkerofresponse
AT bellettibarbara manyfacetsofmir223incanceroncosuppressoroncogenicdrivertherapeutictargetandbiomarkerofresponse